FORM 53-901F

SECURITIES ACT

MATERIAL CHANGE REPORT UNDER
SECTION 85(1) OF THE SECURITIES ACT (BRITISH COLUMBIA)
AND EQUIVALENT LEGISLATION OF OTHER JURISDICTIONS

Item 1.	REPORTING ISSUER
	Cardiome Pharma Corp.
	6190 Agronomy Road, 6th Floor
	Vancouver, BC        V6T 1Z3
Item 2.	DATE OF MATERIAL CHANGE
	March 31, 2006
Item 3.	PRESS RELEASE
	March 31, 2006 - Vancouver, British Columbia (Canada)
	March 31, 2006 – Deerfield, Illinois (USA)
Item 4.	SUMMARY OF MATERIAL CHANGE
	Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. announced Astellas’ submission of a New Drug Application (NDA) to the United States Food & Drug Administration (FDA) seeking approval to market the intravenous formulation of RSD1235, an investigational new drug for the acute conversion of atrial fibrillation.
Item 5.	FULL DESCRIPTION OF MATERIAL CHANGE
	See attached press release
Item 6.	RELIANCE ON SECTION 85(2) OF THE SECURITIES ACT (BRITISH COLUMBIA) AND EQUIVALENT LEGISLATION OF OTHER JURISDICTIONS
	Not Applicable.
Item 7.	OMITTED INFORMATION
	Not Applicable.
Item 8.	SENIOR OFFICER
	Name:               Doug Janzen
	Title:                 Chief Financial Officer
	Phone No.:      604-677-6905
Item 9.	STATEMENT OF SENIOR OFFICER
	The foregoing accurately discloses the material change referred to herein.

Dated at Vancouver, British Columbia, this 3rd day of April, 2006.

CARDIOME PHARMA CORP.
Per:	“Doug Janzen”
	Doug Janzen,
	Chief Financial Officer

IT IS AN OFFENCE FOR A PERSON TO MAKE A STATEMENT IN A DOCUMENT REQUIRED TO BE FILED OR FURNISHED UNDER THE ACT OR THIS REGULATION THAT, AT THE TIME AND IN THE LIGHT OF THE CIRCUMSTANCES UNDER WHICH IT IS MADE, IS A MISREPRESENTATION.